MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
Agreement On Tasigna Generics Represents First Such Deal For A Cancer Medicine
The Medicines Patent Pool has struck a milestonedeal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”
You may also be interested in...
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.
The Union for International Cancer Control and the World Health Organization are prioritizing off-patent drugs in their efforts to facilitate oncology medicine access in developing nations.
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.